Penumbra, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (42)

View All

Latest Posts

About This Stock More About This Stock
Don't Overlook These Top Medical Stocks As Q1 Earnings Approach
Article By: Zacks Investment Research
Tuesday, May 7, 2024 3:00 AM EDT
While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and Penumbra is hard to ignore.
In this article: LGND, PEN, OSCR
Read
Bull Of The Day: Penumbra
Article By: Kevin Cook
Friday, September 22, 2023 7:47 AM EDT
After a solid beat-and-raise Q2 reported in early August, upward estimate revisions by six Wall Street analysts moved PEN to a Zacks #1 Rank. And Wells Fargo raised their PT from $320 to $337.
In this article: PEN Also: MDT, UAL
Read
Penumbra Downgraded To Neutral From Buy At BTIG
Article By: The Fly
Wednesday, December 16, 2020 7:08 AM EDT
BTIG analyst Ryan Zimmerman downgraded Penumbra to Neutral from Buy.
In this article: PEN
Read
Penumbra Slides 5% After Spruce Point Calls For Up To 55% Downside
Article By: The Fly
Wednesday, July 31, 2019 1:00 PM EDT
Shares of Penumbra are down 5% in early trading after short-selling focused research firm Spruce Point issued a short report on the stock, outlining their thesis why the share price is at risk for 40%-55% downside risk.
In this article: PEN
Read
Bull Of The Day: Penumbra (PEN)
Article By: Kevin Cook
Tuesday, September 25, 2018 2:30 PM EDT
Penumbra made a strong swing to sustainable profitability this year on the back of projected 27.5% sales growth from last year's $333 million to over $425 million in revenue.
In this article: PEN Also: ABT, BAX, EW, JNJ, MDT, SYK, IART, AXGN, MZOR
Read
All Posts

Latest Tweets for $PEN

No tweets yet!

PARTNER HEADLINES